All Stories

  1. New Approach Methodologies ( NAMs ): Guiding Clinical Predictions through Human‐Relevant Evidence
  2. Photocatalytic coupling of unprotected sugars and N-heteroarenes
  3. Enhancing CYP450-Ligand Binding Predictions: A Comparative Analysis of Ligand-Based and Hybrid Machine Learning Models
  4. Metabolome alterations in pediatric metabolically unhealthy obesity are primarily linked to abnormal glucose homeostasis
  5. Evaluation of Four Semi‐Mechanistic Models for Predicting Glycemic Control With a Glucagon Receptor Antagonist in People With Type 2 Diabetes
  6. Comment on “Ticagrelor is Associated with Increased Rosuvastatin Blood Concentrations in Patients Who Have Had a Myocardial Infarction”
  7. Development of Embryonic Stem Cell-derived Human Cardiomyocytes and Application of Fluorescence Probe Substrate for Characterization of CYP2J2
  8. Catalytic difluorocarbene insertion enables access to fluorinated oxetane isosteres
  9. Developing Mitigation Measures for Full or Partially Missed Nirmatrelvir-Ritonavir Doses using Physiologically-Based Pharmacokinetic Modelling
  10. Elucidating the Phase I metabolism of psilocin in vitro
  11. Application of physiologically‐based pharmacokinetic modeling to inform dosing decisions for geriatric patients
  12. Ex vivo metabolism kinetics of primary to secondary bile acids via a physiologically relevant human faecal microbiota model
  13. Physiologically‐based pharmacokinetic modelling guided dose evaluations of nirmatrelvir/ritonavir in renal impairment for the management of COVID‐19
  14. Probe Substrate Dependencies in CYP3A4 Allosteric Inhibition: A Novel Molecular Mechanism Involving F–F′ Loop Perturbations
  15. Predictors associated with bleeding and thromboembolic complications in patients taking rivaroxaban-- a Singapore study
  16. Ciprofol is primarily glucuronidated by UGT1A9 and predicted not to cause drug-drug interactions with typical substrates of CYP1A2, CYP2B6, and CYP2C19
  17. Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes
  18. Risk assessment of cultured meat
  19. Unraveling Complexities in the Absorption and Disposition Kinetics of Abiraterone via Iterative PBPK Model Development and Refinement
  20. Role of Cytochrome P450 2C8 in Drug–Drug Interaction between Amiodarone and Nirmatrelvir/Ritonavir Via Physiologically‐Based Pharmacokinetic Modeling
  21. Development and verification of a physiologically‐based pharmacokinetic model of dronedarone and its active metabolite N‐desbutyldronedarone: application to prospective simulation of complex drug‐drug interaction with rivaroxaban.
  22. Lactobacillus paracasei IMC 502 ameliorate type 2 diabetes by mediating gut microbiota‐SCFAs ‐hormone/inflammation pathway in mice
  23. Identification of Optimal Urinary Biomarkers of Synthetic Cannabinoids BZO-HEXOXIZID, BZO-POXIZID, 5F-BZO-POXIZID, and BZO-CHMOXIZID for Illicit Abuse Monitoring
  24. Inhibition of cytochrome P450 2J2-mediated metabolism of rivaroxaban and arachidonic acid by ibrutinib and osimertinib
  25. Physiologically Based Pharmacokinetic Modelling‐Guided Dose Management of Oral Anticoagulants when Initiating Paxlovid for COVID ‐19 Treatment
  26. Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban
  27. Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore
  28. Metabolic Activation of the Acrylamide Michael Acceptor Warhead in Futibatinib to an Epoxide Intermediate Engenders Covalent Inactivation of Cytochrome P450 3A
  29. Quantification of the irreversible fibroblast growth factor receptor inhibitor futibatinib by UPLC-MS/MS: Application to the metabolic stability assay in human liver microsomes for the estimation of its in vitro hepatic intrinsic clearance
  30. Rational deuteration of dronedarone attenuates its toxicity in human hepatic HepG2 cells
  31. Site-directed deuteration of dronedarone preserves cytochrome P4502J2 activity and mitigates its cardiac adverse effects in canine arrhythmic hearts
  32. Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminate in Mechanism-Based Inactivation of Cytochrome P450 3A
  33. Antidiabetic effects of multi-species probiotic and its fermented milk in mice via restoring gut microbiota and intestinal barrier
  34. Febuxostat and its Major Acyl Glucuronide Metabolite are Potent Inhibitors of Organic Anion Transporter 3: Implications for Drug‐Drug Interactions with Rivaroxaban
  35. Transesterification of Indazole-3-Carboxamide Synthetic Cannabinoids: Identification of Metabolite Biomarker for Diagnosing Co-Abuse of 5F-MDMB-PINACA and Alcohol
  36. Inhibition of cytochrome P450 enzymes and uridine 5′-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions
  37. Application of a PBPK Model of Rivaroxaban to Prospective Simulations of Drug‐Drug‐Disease Interactions with Protein Kinase Inhibitors in CA‐VTE
  38. Model-Based Risk Prediction of Rivaroxaban with Amiodarone for Moderate Renal Impaired Elderly Population
  39. Atypical kinetics of cytochrome P450 2J2: Epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors
  40. Urinary Metabolite Biomarkers for the Detection of Synthetic Cannabinoid ADB-BUTINACA Abuse
  41. Preliminary discovery of novel markers for human cell line activation test (h-CLAT)
  42. Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4
  43. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5
  44. Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib
  45. Application of a PBPK Model of Rivaroxaban to Prospective Simulations of Drug-Drug-Disease Interactions with Protein Kinase Inhibitors in CA-VTE
  46. Investigation of the arcane inhibition of human organic anion transporter 3 by benzofuran antiarrhythmic agents
  47. Fructose intolerance is not associated with malabsorption in patients with functional gastrointestinal disorders
  48. Mechanism-based Inactivation of Cytochrome P450 3A4 by Benzbromarone
  49. An exploratory analysis of effects of poyendarone, a deuterated analogue of dronedarone, on the canine model of paroxysmal atrial fibrillation
  50. Diagnosing intake and rationalizing toxicities associated with 5F-MDMB-PINACA and 4F-MDMB-BINACA abuse
  51. A compromised developmental trajectory of the infant gut microbiome and metabolome in atopic eczema
  52. Tryptophan–kynurenine ratio as a biomarker of bladder cancer
  53. Combination Bacillus Calmette-Guérin and indoleamine 2,3-dioxygenase 1 inhibitor therapy of murine orthotopic bladder cancer
  54. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen
  55. Increased Protein S-Glutathionylation in Leber’s Hereditary Optic Neuropathy (LHON)
  56. How the Deuteration of Dronedarone Can Modify Its Cardiovascular Profile: In Vivo Characterization of Electropharmacological Effects of Poyendarone, a Deuterated Analogue of Dronedarone
  57. Predicting human tissue exposures to xenobiotics using a bottom-up physiologically-based biokinetic model
  58. Atypical Michaelis-Menten kinetics in cytochrome P450 enzymes: A focus on substrate inhibition
  59. Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban
  60. Bottom-up physiologically-based biokinetic modelling as an alternative to animal testing
  61. Faculty cooperation in teaching academic literacy using popular science texts: A case study
  62. Dose-Dependent Increase in Unconjugated Cinnamic Acid Concentration in Plasma Following Acute Consumption of Polyphenol Rich Curry in the Polyspice Study
  63. Reactive Metabolite-induced Protein Glutathionylation: A Potentially Novel Mechanism Underlying Acetaminophen Hepatotoxicity
  64. Rivaroxaban With and Without Amiodarone in Renal Impairment
  65. Recent advances in the applications of metabolomics in eye research
  66. Dronedarone-Induced Cardiac Mitochondrial Dysfunction & Its Mitigation by Epoxyeicosatrienoic Acids
  67. Polyphenol-rich curry made with mixed spices and vegetables benefits glucose homeostasis in Chinese males (Polyspice Study): a dose–response randomized controlled crossover trial
  68. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine
  69. Effects of dronedarone, amiodarone and their active metabolites on sequential metabolism of arachidonic acid to epoxyeicosatrienoic and dihydroxyeicosatrienoic acids
  70. The liver-gut microbiota axis modulates hepatotoxicity of tacrine in the rat
  71. In Silico and in Vitro Interactions between Short Chain Fatty Acids and Human Histone Deacetylases
  72. Inhibition and inactivation of human CYP2J2: Implications in cardiac pathophysiology and opportunities in cancer therapy
  73. A novel LCMSMS method for quantitative measurement of short-chain fatty acids in human stool derivatized with 12 C- and 13 C-labelled aniline
  74. Common deregulated gene expression profiles and morphological changes in developing zebrafish larvae exposed to environmental-relevant high to low concentrations of glucocorticoids
  75. Application of Static Modeling ­­in the Prediction of In Vivo Drug–Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies
  76. Proteo-metabolomics in elucidating mechanisms of acetaminophen toxicity
  77. Targeted LC/MS-based quantitative profiling of 15 gut microbiome-derived short chain fatty acids in infant and adult stool
  78. Dronedarone inhibits CYP2J3 activity in H9c2 cardiomyocytes without mitochondrial toxicity
  79. Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells
  80. Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model
  81. In VitroActivity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B
  82. Phase I Metabolic Stability and Electrophilic Reactivity of 2-Phenylaminophenylacetic Acid Derived Compounds
  83. Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites
  84. Metabolomic Characterizations of Liver Injury Caused by Acute Arsenic Toxicity in Zebrafish
  85. Metabolic Markers for Diabetic Retinopathy
  86. The Isotope-Coded Affinity Tag Method for Quantitative Protein Profile Comparison and Relative Quantitation of Cysteine Redox Modifications
  87. Metabonomic diagnosis of bladder cancer: what are the advantages and considerations?
  88. Gastrointestinal Symptoms and Altered Intestinal Permeability Induced by Combat Training Are Associated with Distinct Metabotypic Changes
  89. Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone
  90. Understanding the cholesterol metabolism-perturbing effects of docosahexaenoic acid by gas chromatography–mass spectrometry targeted metabonomic profiling
  91. Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A
  92. Global Metabonomic and Proteomic Analysis of Human Conjunctival Epithelial Cells (IOBA-NHC) in Response to Hyperosmotic Stress
  93. Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer
  94. Investigation of Host–Gut Microbiota Modulation of Therapeutic Outcome
  95. In VitroPharmacodynamics of Various Antibiotics in Combination against Extensively Drug-Resistant Klebsiella pneumoniae
  96. Metabolic Profiling of CHO-AβPP695 Cells Revealed Mitochondrial Dysfunction Prior to Amyloid-β Pathology and Potential Therapeutic Effects of Both PPARγ and PPARα Agonisms for Alzheimer's Disease
  97. Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib
  98. Metabonomic Profiling of Bladder Cancer
  99. Global fecal microRNA profiling in the identification of biomarkers for colorectal cancer screening among Asians
  100. Metabotyping of Docosahexaenoic Acid - Treated Alzheimer’s Disease Cell Model
  101. Development of an UPLC–MS/MS method for assaying the enzymatic activity of propionyl coenzyme-A carboxylase
  102. Non-invasive fecal metabonomic detection of colorectal cancer
  103. Applications of monolithic materials for sample preparation
  104. Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model
  105. Global gas chromatography/time-of-flight mass spectrometry (GC/TOFMS)-based metabonomic profiling of lyophilized human feces
  106. Urinary Metabotyping of Bladder Cancer Using Two-Dimensional Gas Chromatography Time-of-Flight Mass Spectrometry
  107. Metabolically Functional Hepatocyte-Like Cells from Human Umbilical Cord Lining Epithelial Cells
  108. An automated Pearson's correlation change classification (APC3) approach for GC/MS metabonomic data using total ion chromatograms (TICs)
  109. Gas Chromatography/Mass Spectrometry-Based Metabonomics
  110. Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy
  111. Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties
  112. Optimizing hollow-fiber-based pharmacokinetic assay via chemical stability study to account for inaccurate simulated drug clearance of rifampicin
  113. Metabonomic Profiling of TASTPM Transgenic Alzheimer’s Disease Mouse Model
  114. An Investigation of the Bioactivation Potential and Metabolism Profile of Zebrafish versus Human
  115. LC-MS-based metabolic characterization of high monoclonal antibody-producing Chinese hamster ovary cells
  116. Thomas O. Metz (Ed.): Metabolic profiling. Methods and protocols
  117. Interaction of Lapatinib with Cytochrome P450 3A5
  118. ChemInform Abstract: Trend Analysis of Metabonomics and Systematic Review of Metabonomics-derived Cancer Marker Metabolites
  119. Metabotyping of human colorectal cancer using two-dimensional gas chromatography mass spectrometry
  120. Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence
  121. Metabonomics
  122. Reversible time-dependent inhibition of cytochrome P450 enzymes by duloxetine and inertness of its thiophene ring towards bioactivation
  123. Global urinary metabolic profiling procedures using gas chromatography–mass spectrometry
  124. Efficiency of a miniaturized silica monolithic cartridge in reducing matrix ions as demonstrated in the simultaneous extraction of morphine and codeine from urine samples for quantification with liquid chromatography-tandem mass spectrometry (LC-MS/MS)
  125. Characterization of The Human Tear Metabolome by LC–MS/MS
  126. Use of Urine Volatile Organic Compounds To Discriminate Tuberculosis Patients from Healthy Subjects
  127. Metabolic Profiling of 3-Nitropropionic Acid Early-Stage Huntington’s Disease Rat Model Using Gas Chromatography Time-of-Flight Mass Spectrometry
  128. Extraction of ketamine from urine using a miniature silica monolithic cartridge followed by quantification with liquid chromatography tandem mass spectrometry (LC-MS/MS)
  129. Metabolic Intermediate Complex Formation of Human Cytochrome P450 3A4 by Lapatinib
  130. Zebrafish for drug toxicity screening: bridging thein vitrocell-based models andin vivomammalian models
  131. Ultra-pressure liquid chromatography/tandem mass spectrometry targeted profiling of arachidonic acid and eicosanoids in human colorectal cancer
  132. Anti-proliferative effects of raw and steamed extracts of Panax notoginseng and its ginsenoside constituents on human liver cancer cells
  133. Comparative evaluation of software for retention time alignment of gas chromatography/time-of-flight mass spectrometry-based metabonomic data
  134. Trend analysis of metabonomics and systematic review of metabonomics-derived cancer marker metabolites
  135. Metabolic footprinting of tumorigenic and nontumorigenic uroepithelial cells using two-dimensional gas chromatography time-of-flight mass spectrometry
  136. Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib
  137. On-line chromatographic screening of matrix metalloproteinase inhibitors using immobilized MMP-9 enzyme reactor
  138. Application of silica-based monolith as solid phase extraction cartridge for extracting polar compounds from urine
  139. Direct toxicity effects of sulfo-conjugated troglitazone on human hepatocytes
  140. Ultra-high performance liquid chromatography/time-of-flight mass spectrometry (UHPLC/TOFMS) for time-dependent profiling of raw and steamed Panax notoginseng
  141. Noninvasive Urinary Metabonomic Diagnosis of Human Bladder Cancer
  142. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity
  143. A sensitive LC/MS/MS bioanalysis assay of orally administered lipoic acid in rat blood and brain tissue
  144. Fluorescence-Based Liver Microsomal Assay for Screening of Pharmaceutical Reactive Metabolites Using a Glutathione Conjugated 96-Well Plate
  145. Metabolic Profiling of Rat Brain and Cognitive Behavioral Tasks: Potential Complementary Strategies in Preclinical Cognition Enhancement Research
  146. Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity
  147. Development and validation of a gas chromatography/mass spectrometry method for the metabolic profiling of human colon tissue
  148. Pharmaceutical metabolite profiling using quadrupole/ion mobility spectrometry/time-of-flight mass spectrometry
  149. Distribution study of orally administered lipoic acid in rat brain tissues
  150. Metabolic Profiling of Human Colorectal Cancer Using High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance (HR-MAS NMR) Spectroscopy and Gas Chromatography Mass Spectrometry (GC/MS)
  151. Development and validation of a gas chromatography/mass spectrometry metabonomic platform for the global profiling of urinary metabolites
  152. Metabonomics investigation of human urine after ingestion of green tea with gas chromatography/mass spectrometry, liquid chromatography/mass spectrometry and1H NMR spectroscopy
  153. Oxidative Bioactivation and Toxicity of Leflunomide in Immortalized Human Hepatocytes and Kinetics of the Non-Enzymatic to Its Major etabolitie, A77 1726
  154. Prevention of acetaminophen (APAP)-induced hepatotoxicity by leflunomide via inhibition of APAP biotransformation to N-acetyl-p-benzoquinone imine
  155. Gas chromatography/mass spectrometry in metabolic profiling of biological fluids
  156. Investigation of the Drug–Drug Interaction Between α-Lipoic Acid and Valproate via Mitochondrial β-oxidation
  157. Bonding interfaces in wafer-level metal/adhesive bonded 3D integration
  158. Evaluation of BEH C18, BEH HILIC, and HSS T3 (C18) Column Chemistries for the UPLC-MS-MS Analysis of Glutathione, Glutathione Disulfide, and Ophthalmic Acid in Mouse Liver and Human Plasma
  159. Enhancing pharmaceutical analysis laboratory classes via the measurement of minerals in Berocca® effervescent tablets
  160. In Vitro Metabolism of Leflunomide by Mouse and Human Liver Microsomes
  161. Pharmacokinetic study of intraperitoneally administered troglitazone in mice using ultra-performance liquid chromatography/tandem mass spectrometry
  162. Ultra-performance liquid chromatography/time-of-flight mass spectrometry based metabolomics of raw and steamedPanax notoginseng
  163. Detection of aristolochic acid I, tetrandrine and fangchinoline in medicinal plants by high performance liquid chromatography and liquid chromatography/mass spectrometry
  164. Modeling Caco-2 permeability of drugs using immobilized artificial membrane chromatography and physicochemical descriptors
  165. Hydrophilic interaction liquid chromatography with tandem mass spectrometry for the determination of underivatized dencichine (β-N-oxalyl-L-α,β-diaminopropionic acid) inPanax medicinal plant species
  166. Application of Visual Basic in High-Throughput Mass Spectrometry-Directed Purification of Combinatorial Libraries
  167. Preparation and characterization of immunogens for antibody production against metanephrine and normetanephrine
  168. An automated LC method for the small-scale purification of organic molecules derived from combinatorial libraries
  169. Evaluation of degradation of urinary catecholamines and metanephrines and deconjugation of their sulfoconjugates using stability-indicating reversed-phase ion-pair HPLC with electrochemical detection
  170. High-performance liquid chromatographic assay for catecholamines and metanephrines using fluorimetric detection with pre-column 9-fluorenylmethyloxycarbonyl chloride derivatization
  171. High-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometric method for the analysis of catecholamines and metanephrines in human urine
  172. The value of analytical assays that are stability-indicating
  173. Enantiomeric separation of tramadol hydrochloride and its metabolites by cyclodextrin-mediated capillary zone electrophoresis